Virbac Stock

Virbac Equity

The The Equity of Virbac (VIRP.PA) as of Aug 19, 2026 is 1.13 B EUR. In the previous year, The Equity was 1.04 B EUR — a change of 7.87% (higher).

Equity

1.13 BEUR

YoY

7.87%

Last updated:

In 2026, Virbac's equity was 1.13 B EUR, a 7.87% increase from the 1.04 B EUR equity in the previous year.

Access this data via the Eulerpool API

Virbac Stock analysis

What does Virbac do? Virbac SA is a French company specializing in animal medicines and care products. The company was founded in 1968 by Pierre Richard Dick, who studied veterinary medicine at the École nationale vétérinaire d'Alfort and gained experience as a veterinarian. Since its founding, Virbac SA has been headquartered near Carros, France and operates worldwide. The business model of Virbac SA is to offer a wide range of products to veterinarians and pet owners, aiming to ensure optimal health, care, and quality of life for their pets. This includes everything from vaccines, diagnostics, and medications to grooming products that veterinarians and pet owners need to ensure optimal pet healthcare. Virbac SA has five main business areas, namely livestock, pets, horses, hygiene products, and specialties. The livestock sector includes products such as feed additives and antiparasitics tailored to the specific needs of cattle, pigs, poultry, and fish. In the pets sector, Virbac SA offers products specifically tailored to dogs, cats, birds, and other pets. This includes both disease prevention and treatment products. In the horse sector, the company offers products for the maintenance, care, and health of horses. Another division of Virbac SA is hygiene products. The company offers a wide portfolio of products and solutions that support both veterinarians and pet owners in ensuring the health and care of animals. This ranges from infection control products to animal-specific shampoos and grooming items. The specialties sector, on the other hand, includes specialized products such as targeted diagnostics, therapeutics, and dietary supplements. The constant focus on research and development also leads to innovative product launches that consistently meet the highest quality standards. An example of this is the scientifically developed dental hygiene product line that improves both the oral health and breath quality of dogs and cats. For this, Virbac SA also receives awards from the Veterinary Center for Clinical Medicine in Munich. Through a systematic international expansion strategy, Virbac SA is now present in more than 100 countries. The company employs over 4,800 people worldwide and achieved a turnover of 954 million euros in 2019. Overall, Virbac SA stands for consistently high product quality and a strong customer orientation. With a combination of expertise and extensive scientific research and development, particularly in the field of animal health and care, the company is an important player in the global animal medicine manufacturing market. Virbac is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Virbac's Equity

Virbac's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Virbac's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Virbac's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Virbac's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Virbac’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Virbac stock

The Equity of Virbac is 1.13 B EUR in 2026.

The Equity of Virbac changed from 1.04 B EUR to 1.13 B EUR, representing a 7.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Virbac since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Virbac historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Virbac

All Key Metrics — Virbac